Exhibit 10.17


 





MANUFACTURING
AND LICENSE AGREEMENT


 


Between


 


Elite Pharmaceuticals, Inc.


 


and


 


Epic Pharma LLC





 


 


 


 


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 


 









    	 



    	 



    

 


MANUFACTURING AND LICENSE AGREEMENT


 


This License Agreement (“Agreement”)
is entered into as of the 2nd day of October, 2013 by and between EPIC PHARMA LLC,
a Delaware limited liability company (“EPIC”), and ELITE PHARMACEUTICALS, INC., a Nevada corporation and ELITE
LABORATORIES, INC. (a subsidiary of Elite Pharmaceuticals, Inc.), a Delaware corporation (collectively, “ELITE”).


 


WHEREAS, ELITE has
ownership rights to products/ANDAs specified on Schedule A (the “Exclusive Products”) and Schedule D (the “Non-Exclusive
Products”), together (the “Products”) as of October 1, 2013, and EPIC wishes to license from ELITE the right
to manufacture, market and sell the Products on the terms and conditions set forth in this Agreement;


 


NOW, THEREFORE, in
consideration of the mutual covenants and agreements set forth in this Agreement, and for other good and valuable consideration,
the receipt of which is hereby acknowledged, the parties hereto agree as follows:


  




GRANT OF LICENSE


 


1.1Exclusive
Product License. ELITE hereby grants to EPIC a license (“License” or “Licensing Rights”) without the
right to further sublicense, to manufacture, market and sell the Exclusive Products as listed in Schedule A in the United States,
including the right to reference the ANDA Number, where appropriate, for approval to market the Products in the United States.


 


1.2Non-Exclusive
Products License. ELITE hereby grants to EPIC a non-exclusive license (“Non-Exclusive License” or “Non-Exclusive
Licensing Rights”) without the right to further sublicense, to manufacture, market and sell the Non-Exclusive Products as
listed in Schedule D in the United States, including the right to reference the ANDA Number, where appropriate, for approval to
market the Non-Exclusive Products in the United States. ELITE shall be the only other company allowed to manufacture, market and
sell the Non-Exclusive Products and ELITE shall only sell to clinics. EPIC shall not share in any profits from Non-Exclusive Products
sold by ELITE.


 


1.3Marketing
Rights. ELITE hereby grants to EPIC exclusive marketing rights (“Marketing Rights”) to market and sell the Products
in the United States, and Puerto Rico). ELITE agrees that it shall not (and it shall not authorize, permit or suffer any of its
affiliates to), directly or indirectly, sell or distribute a Product in United States at any time during the term of this agreement
unless specifically authorized or excluded under the terms of this Agreement


 


1.4Trademarks.
EPIC agrees and acknowledges that it shall not acquire by virtue of this Agreement any interest in any trademarks or trade names
of ELITE.


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







  






    	2



    	 



    

 


1.5Manufacturing.
ELITE hereby grants to EPIC rights to manufacture the Products for marketing and sales of the Products by EPIC in the United States
and Puerto Rico.


  


1.6Regulatory
and Pharmacovigilance. EPIC shall be responsible for all regulatory and pharmacovigilance matters related to these Products.


 


1.7Licensed
Trade Secrets. The information exchanged between ELITE and EPIC pursuant to this Agreement is expressly subject to the Mutual
Confidentiality and Non-Disclosure Agreement entered into by the parties and dated October 8, 2008 (the “Confidentiality
Agreement”) and whose term is hereby made coterminous with this Agreement.


 


1.8Improvements.
Any new information, developments, or improvements relating to the Products subject to this Agreement, and any patent or copyright
rights arising from or related thereto (collectively, “Improvements”) will be owned solely by ELITE but shall be automatically
included in the License, and if EPIC develops an Improvement that may be used beyond the Products which are the subject of this
Agreement, then ELITE does now automatically grant a worldwide, non-exclusive, irrevocable, royalty-free right for EPIC to use
the Improvement.


 


1.9Quality
Agreement. In conjunction with the execution of this Agreement, the parties shall execute a Quality Agreement.


 


1.10Site
Transfer. EPIC shall be responsible for all costs related to the site transfer for all Products.


 




COMPENSATION


 


2.1.License
Fee, Milestone, and Transfer Cost Payments. In return for the Licensing Rights described in this Agreement, EPIC shall pay
to ELITE the milestone payments (“Milestone Payments”) and a license fee (“License Fee”) compensation specified
in Schedule B. If ELITE manufactures any product for sale by EPIC, then the transfer cost for the Product shall be ${***}
per 1000 units in any configuration required by marketing plus the cost of the API at cost (as documented by invoices for the API)


 


2.2.Records.
EPIC shall keep complete and accurate records of all manufacture and sales of the Products and the calculation of product costs,
net sales and gross profit of the Products. EPIC shall also provide a detailed summary of the Cost of Goods for each product on
Schedule A. ELITE shall have the right, at ELITE’s expense and after thirty (30) days’ prior written notice to EPIC,
through an independent certified public accountant, on a mutually agreeable date, to examine such records at any time within one
(1) year after the due date of the License Fee payments to which such records relate, during regular business hours, during the
life of this Agreement and for twelve (12) months after expiration of the last production lot of Product sold by EPIC, in order
to verify the accuracy of the reports to be made under this Agreement. If the accountant determines that EPIC has under-compensated
ELITE, the findings shall be shared with EPIC. If EPIC agrees that EPIC has not paid ELITE all of the compensation ELITE was entitled
to receive, or it is later determined that EPIC did not pay all of the compensation due to ELITE, then EPIC shall pay the proper
amount of compensation and all costs and expenses incurred by ELITE to hire the accountant and all of the accountant’s expenses,
and all legal expenses, to obtain the appropriate compensation. If EPIC disputes in good faith the accuracy of the results of such
examination, the parties will retain a second independent certified public accountant whose examination will be binding upon both
parties. The losing party will pay all of the expenses of both independent certified public accountant examinations.


  


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 



    	3



    	 



    




 


2.3.Reports.
EPIC will provide Reports as stipulated in Schedule B.


 


2.4.Payments
by EPIC. 


 


		(a)	All Milestone Payments will be made by check and mailed to ELITE within ten (10) days after the payment becomes due.



 


		(b)	The License Fee shall be paid to ELITE in monthly payments based upon the previous month’s Products that EPIC shipped
to its customers. All License Fee payments shall be made by check and mailed to ELITE within thirty (30) days after the end of
each calendar month. A copy of the Report for the prior month will accompany the check.



 


		(c)	A late fee of 1% per month will be accrued for all payments which EPIC fails to pay when due.



 




TERM AND TERMINATION


 


3.1.Term.
This Agreement shall become effective as of the date hereof and shall continue until five (5) years from such date (the “Initial
Term”), unless terminated earlier by mutual agreement of the parties or by one of the parties in accordance with this Article
3; provided further that the parties shall have the option, by mutual agreement, to extend the Initial Term of this Agreement for
an additional five (5) years (a “Renewal Term” and collectively with the Initial Term, the “Term”) by the
parties exchanging written notice of such election not less than six (6) months prior to the expiration of the Initial Term.


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 




    	4



    	 



    

  


3.2.Modification
for Lack of Licensing Fees and Minimum Unit Volumes.


 


		(a)	EPIC hereby agrees to exert commercially reasonable efforts and shall devote the same efforts to marketing the Products that
EPIC exerts for its other major pharmaceutical products being marketed in the United States.



 


		(b)	If after twelve (12) months of a Product’s launch, the Gross Profit declines for any Product to the point that the License
Fee paid to ELITE is less than $100,000 for a six (6) month period for that Product, then ELITE may terminate the Marketing Rights
granted hereunder to EPIC as it relates to that individual Product. If ELITE desires to terminate the Marketing Rights granted
hereunder, then ELITE shall give EPIC ninety (90) days written notice that it will no longer have the Marketing Rights to sell
the particular Product.



 


If EPIC’s unit volume sales
of an API specific group of Products (“ Product Group”), (initially defined as Isradipine, Dantrolene, or Loxapine
Product Groups), does not meet its minimum annual unit volume forecast for that Product Group in the initial launch year, or does
not meet its subsequent minimum annual unit volume forecast (as defined in Schedule C) for a Product Group, then EPIC shall have
the following six (6) months to achieve one-half of the prior year’s minimum annual unit volume forecast and if EPIC still
fails to meet such volume minimum during the six months described, then EPIC shall lose its Marketing Rights of such Product Group.


 


3.3.Termination
by Mutual Agreement. The parties may terminate this Agreement any time by mutual written agreement.


 


3.4.Termination
by Breach. Upon the breach or default in the performance or observance of any of the material provisions of this Agreement
by either Party, when such breach or default is not cured by the responsible Party within sixty (60) days after written notice
by the other Party, the other Party may terminate this Agreement upon an additional thirty (30) days written notice to the other
Party. Termination will be without prejudice to either Party to recover any and all damages to which it may be entitled, or to
exercise any other remedies.


 


3.5.Termination
by ELITE Upon Bankruptcy or Reorganization of EPIC. If EPIC enters into any proceeding (whether voluntary or otherwise) in
bankruptcy, reorganization or arrangement for the appointment of a receiver or trustee to take possession of its assets, or any
other proceeding under any law for the relief of creditors or makes an arrangement for the benefit of its creditors, and remains
in such proceeding for 30 days, then ELITE shall retain its rights to the Products and may terminate this Agreement without further
payment to EPIC.


 


3.6.Licensing
Rights upon Termination. Except as otherwise provided in this Agreement, upon termination of this Agreement: all rights, privileges,
and licenses will terminate and revert to ELITE, and EPIC must not thereafter make any use whatsoever of any trade secrets, except
that it is agreed that upon termination notwithstanding any other terms of this Agreement, EPIC may retain one archival copy to
have sufficient information solely to respond to state and federal regulatory inquiries regarding the Products.


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 






    	5



    	 



    

 


3.7.Accrued
Rights. Expiration or termination of this Agreement shall be without prejudice to the right of either Party to receive all
payments accrued and unpaid at the effective date of such expiration or termination, without prejudice to the remedy of either
Party in respect to any previous breach of the representations, warranties or covenants herein contained, without prejudice to
any rights to indemnification set forth herein and without prejudice to any other provision hereof which expressly or necessarily
calls for performance after such expiration or termination. EPIC expressly retains the right to sell Product on-hand after termination
of this Agreement and shall remain bound to pay ELITE the Licensing Fee as provided in this Agreement.


 


3.8.Transition.
If this Agreement is terminated for any reason or if EPIC loses its Marketing Rights for any or all Products, or if EPIC stops
selling for any reasons, EPIC then shall be required to contract manufacture at cost plus {***}%
for a three (3) year period from the date the termination occurs or the date the selling ends whichever comes first.


  




REPRESENTATIONS, WARRANTIES AND COMPETITION, COOPERATION UPON BANKRUPTCY OF ELITE


 


4.1.EPIC
Representations. EPIC hereby represents and warrants to ELITE that (a) it has obtained all necessary licenses, authorizations
and approvals required by applicable Law, including those required by the FDA, DEA or any other applicable regulatory agency to
enter into this Agreement and perform its obligations hereunder; (b) the execution, delivery and performance of this Agreement
by EPIC does not conflict with or constitute a breach of any order, judgment, agreement, or instrument to which it is a party;
(c) the execution, delivery and performance of this Agreement by EPIC does not require the consent of any person; and (d) none
of its officers or directors has ever been convicted of a felony under the laws of the United States for conduct relating to the
development or approval of a drug product or relating to the marketing or sale of a drug product


 


4.2.ELITE
Representations. ELITE hereby represents and warrants to EPIC that (a) it has obtained all necessary licenses, authorizations
and approvals required by applicable Law, including those required by the FDA, DEA or any other applicable regulatory agency to
enter into this Agreement and perform its obligations hereunder; (b) the execution, delivery and performance of this Agreement
by ELITE does not conflict with or constitute a breach of any order, judgment, agreement, or instrument to which it is a party;
(c) the execution, delivery and performance of this Agreement by ELITE does not require the consent of any person; and (d) none
of its officers or directors has ever been convicted of a felony under the laws of the United States for conduct relating to the
development or approval of a drug product or relating to the marketing or sale of a drug product.


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 






    	6



    	 



    

 


4.3.Non-competition
by EPIC. EPIC hereby covenants and agrees that without the prior written consent of ELITE during the Term of this Agreement,
and for 1 year after the last shipment of Product by EPIC if the agreement is terminated due to breach of the Agreement by EPIC,
EPIC will not directly or indirectly market any of the Products Licensed to EPIC by ELITE pursuant to this Agreement. This section
is not intended to prohibit EPIC from marketing and selling a product which addresses the same therapeutic indication as a Product,
as long as that other product does not contain the same API as the Product(s) in this Agreement.


 


4.4.Cooperation
Upon Bankruptcy Event of ELITE. ELITE shall use, and cause its representatives and affiliates to use, best efforts to make
all necessary arrangements and take all required actions to permit EPIC to retain all rights licensed hereunder with respect to
the Products in the event that ELITE (i) is dissolved
or liquidated, (ii) commences a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect
to itself or its debts under any bankruptcy, insolvency or other similar law, (iii) is subject to an involuntary case or other
proceeding seeking liquidation, reorganization or other relief with respect to ELITE and an order for relief entered or such proceeding
has not be dismissed or discharged within sixty (60) days of commencement, (v) has made an assignment for the benefit of creditors,
or (vi) otherwise ceases to conduct business during the Term (each, an “Extraordinary Event”).


 




INDEMNIFICATION AND INSURANCE


 


5.1.ELITE
Indemnity. Subject to Sections 5.2 and 5.4, ELITE shall indemnify and hold harmless EPIC and its Affiliates against all third
party claims, actions, costs, expenses, including court costs and legal fees or other third party liabilities ("Third Party
Liabilities") whatsoever in respect of:


 


		(a)	any breach of any representation, warranty, covenant or similar promise made under this Agreement or arising out of this Agreement;



 


		(b)	any negligence or willful misconduct by ELITE and/or any of its employees; and



 


		(c)	any product liability in connection with the Products caused by ELITE or any third party acting on behalf of ELITE or its Affiliates;



 


5.2.EPIC
Indemnity. Subject to Sections 5.1 and 5.4, EPIC shall indemnify and hold harmless ELITE and its Affiliates against all Third
Party Liabilities whatsoever in respect of:


 


		(a)	EPIC’s and/or it Affiliates’, subcontractors’ or suppliers’ failure to comply with the Product Specifications,
cGMP or applicable Laws;



 


		(b)	the use, marketing, storage, distribution, handling or sale of the Product after the Effective Date by EPIC or any third party,
other than a third party acting on behalf of ELITE or its Affiliates;



 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 






    	7



    	 



    

 


		(c)	any product liability in connection with the Products caused by EPIC or any third party acting on behalf of EPIC or its Affiliates;



 


		(d)	for any Product that is recalled or withdrawn from the market by reason of EPIC’s breach of any warranty or other covenant
under this Agreement or any other agreement with ELITE, ELITE will be entitled to reimbursement of all costs associated with a
recall or withdrawal, including reasonable costs associated with compliance with the recall or withdrawal (including penalties).



 


		(e)	any liabilities arising out of the presence or actions of a EPIC employee at EPIC’s manufacturing and packaging facilities
pursuant to this Agreement; and



 


		(f)	any negligent or wrongful act by EPIC and any breach by EPIC of any representation or warranty, covenant or similar promise
made under this Agreement or arising out of this Agreement.



 


5.3.Procedures
for Indemnification. In the event that a party (the "Indemnified Party") is seeking indemnification under
Sections 5.1 or 5.2, the Indemnified Party shall inform the other party (the "Indemnifying Party") of a claim
as soon as reasonably practicable after the Indemnified Party receives notice of the claim, shall permit the Indemnifying Party
to assume direction and control of the defense of the claim, and shall cooperate as requested by the Indemnifying Party (at the
expense of the Indemnifying Party) in the defense of the claim; provided, however, if the defendants in any such action include
both the Indemnified Party and the Indemnifying Party and the Indemnified Party shall have reasonably concluded that a conflict
may arise between the positions of the Indemnifying Party and the Indemnified Party in conducting the defense of any such action
or that there may be legal defenses available to it that are different from or additional to those available to the Indemnifying
Party, the Indemnified Party shall have the right to select separate counsel to assume such legal defenses and to otherwise participate
in the defense of such action or on behalf of the Indemnified Party. No Indemnifying Party shall, without the prior written consent
of the Indemnified Party, settle or compromise or consent to the entry of judgment with respect to any pending or threatened action
or claim whatsoever, in respect of which indemnification could be sought under Sections 6.1 or 6.2 (whether or not the Indemnified
Party is an actual or potential party thereto), unless such settlement, compromise or consent (i) includes an unconditional release
of the Indemnified Party in form and substance reasonably satisfactory to the Indemnified Party from all liability arising out
of such action or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by
or on behalf of the Indemnified Party. The Indemnifying Party shall not be liable for settlement of any pending or threatened action
or any claim whatsoever that is effected without its written consent (which consent shall not be unreasonably withheld or delayed).


 


5.4.Mitigation.
In the event of any occurrence which may result in either party becoming liable under Section 5.1 or Section 5.2, each party
shall use its best efforts to take such actions as may be reasonably necessary to mitigate the damages payable by the other party
under Section 5.1 or Section 5.2, as the case may be.


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 






    	8



    	 



    

 


5.5.Limitation
of Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED HEREIN, IN NO EVENT SHALL ANY PARTY, ITS DIRECTORS, OFFICERS,
EMPLOYEES, AGENTS OR AFFILIATES BE LIABLE TO THE OTHER PARTIES FOR ANY CLAIMS RELATED TO LOST PROFITS AND GOODWILL, WHETHER BASED
UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT.


 


5.6.Insurance.
Each party shall maintain commercial general liability insurance through the term of this Agreement upon launch of the first Product,
which insurance shall afford limits of not less than $5,000,000 for each occurrence for personal injury or property damage liability.
Furthermore, each party shall maintain product liability insurance, through the term of this Agreement upon launch of the first
Product and for a period of three (3) years thereafter, which insurance shall afford limits of not less than $5,000,000 in
the aggregate per annum with respect to product and completed operations liability. This insurance shall be written to cover claims
incurred, discovered, manifested, or made during or after the expiration of this Agreement. Each party shall provide the other
with a certificate of insurance evidencing the above and showing the name of the issuing company, the policy number, the effective
date, the expiration date and the limits of liability. The insurance certificate shall further provide for a minimum of thirty (30)
days' written notice to the insured of a cancellation of, or material change in, the insurance. If a party is unable to maintain
the insurance policies required under this Agreement through no fault on the part of such party, then such party shall forthwith
notify the other party in writing and the parties shall in good faith negotiate appropriate amendments to the insurance provision
of this Agreement in order to provide adequate assurances. In the event that either a customer or an insurer of either party requires
such party to increase its insurance limits above the $5,000,000 described above for any policy, then the other party to this Agreement
must also match the required insurance increase, so that the parties to this Agreement are carrying the same insurance policy limits.
It is the express intention of the parties that the parties shall endeavor to avoid insurance policy limits above $10,000,000.


 




MISCELLANEOUS


 


6.1.Waiver;
Remedies and Amendment. Any waiver by any party hereto of a breach of any provisions of this Agreement will not be implied
and will not be valid unless such waiver is recited in writing and signed by such party. Failure of any party to require, in one
or more instances, performance by the other party or parties in strict accordance with the terms and conditions of this Agreement
will not be deemed a waiver or relinquishment of the future performance of any such terms or conditions or of any other terms and
conditions of this Agreement. A waiver by any party of any term or condition of this Agreement, including this Section 5.1, shall
be valid only if in writing and will not be deemed or construed to be a waiver of such term or condition for any other term. All
rights, remedies, undertakings, obligations and agreements contained in this Agreement will be cumulative and none of them will
be a limitation of any other remedy, right, undertaking, obligation or agreement of any party. This Agreement may not be amended
except in a writing signed by all parties.


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 






    	9



    	 



    

 


6.2.Affiliates,
Assignment, No Inconsistent Agreements. EPIC may not assign its rights and obligations hereunder without the prior written
consent of ELITE. Neither EPIC nor ELITE will enter into any agreement that is inconsistent with its obligations hereunder.


 


6.3.Counterparts.
This Agreement may be executed in any number of counterparts, each of which when so executed will be deemed to be an original and
all of which when taken together will constitute this Agreement.


 


6.4.Governing
Law; Dispute Resolution; Venue. This Agreement will be governed by and construed in accordance with the laws of the state of
New York without regard to conflict of law or choice of law rules. Any controversy or claim pursuant to this Agreement or the breach
thereof shall be referred for decision forthwith to a senior executive of each Party not directly involved in the dispute. If no
agreement is reached within thirty (30) days of the request by one Party to the other to refer the same to such senior executive,
then such controversy or claim shall be settled by arbitration in accordance with the Commercial Arbitration Rules of the American
Arbitration Association; such arbitration to be held in Rockford, Illinois on an expedited basis. Judgment upon the award rendered
by the Arbitrator(s) may be entered in any court having jurisdiction thereof.


 


6.5.Headings.
The headings set forth at the beginning of the various sections of this Agreement are for convenience and form no part of the Agreement
between the parties.


 


6.6.Notices.
All notices, requests, instructions, consents and other communications to be given pursuant to this Agreement shall be in writing
and shall be deemed received (a) on the same day if delivered in person, by same-day courier or by facsimile, electronic mail or
other electronic transmission, (b) on the next day if delivered by overnight mail or courier, or (c) on the date indicated on the
return receipt, or if there is no such receipt, on the third calendar day (excluding Sundays) if delivered by certified or registered
mail, postage prepaid, to the party for whom intended to the following addresses:


 


	If to EPIC:	 
	
        EPIC

        22715 North Conduit Avenue

        Laurelton, NY 11413

        Attn: President

         
	 
	 	 
	If to ELITE:	 
	
        ELITE PHARMACEUTICALS, Inc.

        165 Ludlow Avenue

        Northvale, New Jersey 07647

        Attention: President and CEO
	 
	 	 


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 






    	10



    	 



    

 


6.7 Notice. Each
party may by written notice given to the other in accordance with this Agreement change the address to which notices to such party
are to be delivered.


 


6.8
Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be invalid or unenforceable,
it will be modified, if possible, to the minimum extent necessary to make it valid and enforceable or, if such modification
is not possible, it will be stricken and the remaining provisions will remain in full force and effect.


 


6.9 Survival. The
rights and obligations which accrue to a party during the term of this agreement shall survive the termination of this Agreement.


 


6.10 Force Majeure.
No party to this Agreement will be liable for failure or delay in the performance of any of its obligations hereunder, if such
failure or delay is due to causes beyond its reasonable control including, without limitation, acts of God, earthquakes, fires,
strikes, acts of war, or intervention of any governmental authority, but any such delay or failure will be remedied by such party
as soon as possible after the removal of the cause of such failure or delay.


 


6.11 Entire Understanding.
This Agreement, including the schedules attached hereto, contains the entire understanding relative to the matters addressed herein,
and supersedes all prior and collateral communications, reports, and understandings, if any, between the parties regarding the
matters addressed herein.


 


6.12 Drafting.
The parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question
of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or
burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.


 


6.13 Not a Joint
Venture. This Agreement does not constitute or create (and the Parties do not intend to create hereby) a joint venture, pooling
arrangement, Partnership, or formal business organization of any kind between and among any of the Parties, and the rights and
obligations of the Parties shall be only those expressly set forth herein. The relationship hereby established between EPIC and
ELITE is solely that of licensee and licensor, each is an independent contractor engaged in the operation of its own respective
business. Neither Party shall be considered to be an agent of the other for any purpose whatsoever. Each Party shall be responsible
for providing its own personnel and workers compensation, medical coverage or similar benefits and shall be solely responsible
for the payment of social security benefits, unemployment insurance, pension benefits, withholding any required amounts for income
and other employment-related taxes and benefits of its own employees, and shall make its own arrangements for injury, illness or
other insurance coverage to protect itself, its Affiliates, its subcontractors and personnel from any damages, loss and/or liability
arising out of the performance of this Agreement. Neither Party has the power or authority to act for, represent or bind the other
(or its Affiliates) in any manner.


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 






    	11



    	 



    

 


IN WITNESS WHEREOF,
the parties have executed this Agreement on the date first set forth above.


 


 


 


	ELITE PHARMACEUTICALS, INC.	EPIC PHARMA LLC
	 	 
	 	 
	 	 
	By:   /s/ Nasrat Hakim                          	By:  /s/ Jai Narine                              
	
         

        Name: Nasrat Hakim
	
         

        Name: Jai Narine

	
         

        Title: CEO and President
	
         

        Title: President

	 	 
	Date: 10/2/13                                       	Date: 10/2/13                                     



 


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 



    	12



    	 



    

 


SCHEDULE A


 


Exclusive Product List


 


  


 


	Name	ANDA #
	{***}	{***}
	{***}	{***}
	{***}	{***}
	{***}	{***}
	{***}	{***}
	{***}	{***}


 


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 




    	13



    	 



    





 


SCHEDULE B


 


Compensation
for Licensing Rights


 


Milestone Payments


 


EPIC shall pay to ELITE
Milestone Payments totaling $1,800,000, according to the following schedule:


 


		·	$600,000 shall be due to ELITE upon signing of this License Agreement and shall be paid no later
than November 15th, 2013.



		·	${***} shall be paid to ELITE upon filing for each
Product’s supplement with FDA as listed below:



		·	{***}



		·	{***}



		·	{***}



		·	${***} shall be paid to ELITE five business days after
FDA’s approval of the site transfer or first product launch and/or shipment whichever comes first:



		§	{***}



		§	{***}



		§	{***}



 


License Fee


 


EPIC will pay to ELITE a License Fee that is a percentage of
the product gross profit (“Product Gross Profit”) of EPIC, as defined below, generated on Products sold and shipped
to its customers by EPIC according to the following schedule:


 


		·	50% of Product Gross Profit



 


 


Product Gross Profit is defined as:


 


Net Sales – Cost of Sale - Cost of
Goods = Product Gross Profit.


 


		§	Net Sales is defined as: Net Invoice Price less the following: Charge backs, Buying Groups/Wholesaler Administrative
Fees/Rebates, Allowances, Medicaid and Returns.



 


		§	Cost of Sales is defined as 3% of Net Sales



 


		§	Cost of Goods is defined as ${***} per 1000 units in any configuration required
by marketing plus the cost of the API at cost (as documented by invoices for the API).



 


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 






    	14



    	 



    

 


EPIC shall also provide a detailed summary of the Cost of Goods
for each product on Schedule B that shall be calculated based on GAAP.


 


The calculation of Product Gross Profit and the Licensing Fee
shall be performed by Epic and presented to Elite as a report (“Report”) which shall include the following information:


 


 


REPORT ITEMS


	
         

         

         

         

         

	 	 	 
	Gross Invoice Sales	 	Total Sales for Month
	Cash Discount	 	Cash Discount 
	 	 	 
	Net Invoice Sales	 	Total Sales - Cash Discount
	 	 	 
	Deductions 	 	Allowances (including; Medicaid rebate; state program rebates)  price adjustments; returns; charge backs.
	Net Sales	 	Net Invoice Sales – Deductions
	
         

        Cost of Sales

         
	 	
        3% of Net Sales

         

	
         

        Cost of Goods
	 	Total Units x Unit Cost 
	 	 	 
	 	 	 
	Gross Profit	 	Net Sales less Cost of Goods
	Margin %	 	Margin Percentage (Gross Profit divided by Gross Invoice Sales)
	 	 	 
	Amount Due 	 	Gross Profit $ x 50%
	 	 	 


  


Whenever possible, the Report will be made using actual sales,
charge backs, administrative fees/rebates, price adjustments, and returns; however, in some cases estimated numbers may be required
because of timing of CBs, fees, returns, etc. A true up Report will be completed and presented to ELITE within 60 days after the
end of each calendar year.


  


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 




    	15



    	 



    

 


SCHEDULE C


 


Minimum Annual Unit Forecast for Each
Product Group


 


 





	   	Year 1	Year 2	Year 3	Year 4	Year 5




 





(Percent of Market)


{***}


{***}


{***}


 


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 



    	16



    	 



    

 


SCHEDULE D


 


Non-Exclusive Product
List


 


 


 


 


 


	Name	ANDA #
	{***}	{***}
	{***}	{***}
	{***}	{***}
	{***}	{***}
	{***}	{***}
	{***}	{***}


 


 


 





{***} Confidential portions of this
exhibit have been redacted and filed separately with the Commission pursuant to a confidential treatment request in accordance
with Rule 24b-2 of the Securities Exchange Act of 1934, as amended.


Confidential 







 






    	17